Bruker Corporation (BRKR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bruker Corporation (BRKR) trades at $56.17 with AI Score 56/100 (Grade B). Bruker Corporation develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions. Market cap: $8.55B, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 10, 2026BRKR stock analysis for 2026: Analysts have set a consensus price target of $50.50 for Bruker Corporation, suggesting 10.1% downside from the current price of $56.17. The AI MoonshotScore is 56/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
BRKR: 1/3 scored disciplines lean bearish. Dominant signal: Financial Safety weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Bruker Corporation (BRKR) Healthcare & Pipeline Overview
Bruker Corporation (BRKR) is a global leader in scientific instruments and analytical solutions, serving the life science, NANO, and energy sectors. With a diverse portfolio of mass spectrometry, microscopy, and molecular diagnostics tools, Bruker supports research and development across various industries, maintaining a strong market presence through innovation and strategic collaborations.
What Is the Investment Thesis for BRKR?
Bruker Corporation presents a compelling investment thesis based on its diverse product portfolio, strategic market positioning, and growth opportunities within the scientific instruments and analytical solutions sector. The company's focus on life science, NANO, and energy technologies provides a diversified revenue stream, mitigating risks associated with individual market segments. Bruker's collaboration with Newomics Inc. and its continued innovation in mass spectrometry and microscopy are key catalysts for future growth. With a market capitalization of $8.55B and a gross margin of 45.3%, Bruker demonstrates financial stability and profitability potential. The company's dividend yield of 0.45% offers a modest return for investors. However, the current profit margin of -0.3% warrants attention, indicating potential areas for operational improvement. Ongoing investments in research and development, coupled with strategic acquisitions, are expected to drive long-term value creation. Potential risks include increased competition and fluctuations in research funding, which could impact revenue growth.
Based on FMP financials and quantitative analysis
BRKR Key Highlights
- Market Cap of $8.55B indicates a strong market presence and investor confidence.
- Gross Margin of 45.3% demonstrates efficient cost management and pricing power.
- Dividend Yield of 0.45% provides a modest income stream for investors.
- Beta of 1.20 suggests higher volatility compared to the market, indicating potential for higher returns but also greater risk.
- Collaboration with Newomics Inc. highlights Bruker's commitment to innovation and strategic partnerships.
Who Are BRKR's Competitors?
BRKR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BTSG BrightSpring Health Services, Inc. | $70.50 | -0.27% | $13.8B | 92 |
| KRYS Krystal Biotech, Inc. | $339.22 | -4.41% | $10.0B | 99 |
| GKOS Glaukos Corporation | $155.46 | -0.87% | $9.13B | 33 |
| CHE Chemed Corporation | $513.68 | +0.72% | $6.82B | 89 |
| TGTX TG Therapeutics, Inc. | $53.96 | -1.66% | $8.26B | 71 |
| BIO Bio-Rad Laboratories, Inc. | $301.90 | -0.81% | $8.16B | 76 |
| GMED Globus Medical, Inc. | $76.01 | -1.29% | $10.3B | 97 |
| PODD Insulet Corporation | $167.37 | +2.02% | $11.6B | 83 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BRKR's Key Strengths?
- Diverse product portfolio across life science, NANO, and energy sectors.
- Strong brand reputation and established market presence.
- Extensive intellectual property and patent protection.
- Global sales and service network.
What Are BRKR's Weaknesses?
- Profit margin of -0.3% indicates potential operational inefficiencies.
- High beta of 1.20 suggests higher market volatility.
- Dependence on research and development funding cycles.
- Exposure to regulatory changes and compliance requirements.
What Could Drive BRKR Stock Higher?
- Continuous product innovation and development in mass spectrometry and microscopy.
- Strategic collaborations and acquisitions to expand market reach and product offerings.
- Potential regulatory approvals for new diagnostic solutions.
- Expansion in emerging markets with increasing R&D investments.
What Are the Key Risks for BRKR?
- Negative return on equity (-0.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players and new entrants.
- Economic downturns and reduced research funding.
- Technological obsolescence and disruptive innovations.
- Fluctuations in research and development funding cycles.
- Supply chain disruptions and geopolitical risks.
What Are the Growth Opportunities for BRKR?
- Expansion in the Life Science Market: The increasing demand for advanced analytical tools in drug discovery, proteomics, and genomics presents a significant growth opportunity for Bruker. Bruker's innovative mass spectrometry and microscopy solutions are well-positioned to capture a larger share of this market. Timeline: Ongoing, with continuous product development and strategic partnerships.
- Advancements in NANO Technology: The growing applications of nanotechnology in various industries, including electronics, materials science, and medicine, offer substantial growth potential for Bruker's NANO segment. The market for nanotechnology-based instruments is expected to expand significantly over the next decade. Bruker's atomic force microscopy and X-ray metrology tools provide a competitive edge in this rapidly evolving field. Timeline: Ongoing, with continuous innovation and market penetration.
- Strategic Collaborations and Acquisitions: Bruker's strategy of forming strategic collaborations and acquiring complementary technologies can accelerate its growth and expand its market reach. The collaboration with Newomics Inc. on a LC-MS platform is a prime example. Identifying and integrating synergistic technologies can enhance Bruker's product offerings and strengthen its competitive position. Timeline: Ongoing, with continuous evaluation of potential partnerships and acquisitions.
- Penetration of Emerging Markets: Expanding into emerging markets, such as Asia-Pacific and Latin America, presents a significant growth opportunity for Bruker. These regions are experiencing rapid economic growth and increasing investments in research and development. Bruker's established presence and reputation can facilitate its entry into these markets. Timeline: 2-5 years, with targeted marketing and distribution strategies.
- Development of Advanced Diagnostic Solutions: The increasing demand for rapid and accurate diagnostic solutions, particularly in the healthcare sector, offers a substantial growth opportunity for Bruker. The global molecular diagnostics market is projected to grow significantly, driven by the need for personalized medicine and early disease detection. Bruker's MALDI Biotyper platform and molecular diagnostics kits are well-positioned to capitalize on this trend. Timeline: Ongoing, with continuous product development and regulatory approvals.
What Opportunities Does BRKR Have?
- Expansion in emerging markets with increasing R&D investments.
- Strategic collaborations and acquisitions to enhance product offerings.
- Growing demand for advanced diagnostic solutions in healthcare.
- Increasing applications of nanotechnology in various industries.
What Threats Does BRKR Face?
- Intense competition from established players and new entrants.
- Economic downturns and reduced research funding.
- Technological obsolescence and disruptive innovations.
- Supply chain disruptions and geopolitical risks.
What Are BRKR's Competitive Advantages?
- Strong brand reputation and established market presence.
- Diverse product portfolio and technological expertise.
- Extensive intellectual property and patent protection.
- Global sales and service network.
- High switching costs for customers due to specialized equipment and training.
What Does BRKR Do?
Bruker Corporation, founded in 1991 and headquartered in Billerica, Massachusetts, is a prominent player in the scientific instruments and analytical solutions market. The company operates through three primary segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. Bruker's offerings include life science tools, single and multiple modality systems, life science mass spectrometry, and the MALDI Biotyper platform for rapid pathogen identification. These products cater to a wide range of applications, from research and development to clinical diagnostics. Bruker's evolution has been marked by continuous innovation and strategic expansion into new technologies. The company provides analytical tools for electron microscopes, X-ray instruments, atomic force microscopy instrumentation, and non-contact nanometer resolution solution topography. Additionally, Bruker offers advanced optical fluorescence microscopy instruments and solutions for multi-omics research, drug discovery, and biomarker identification. The company also produces superconducting materials and related devices, serving the energy and research sectors. Bruker's global presence is supported by its commitment to providing comprehensive solutions and services to its customers. The company's collaboration with Newomics Inc. on a LC-MS platform exemplifies its dedication to advancing drug discovery technologies. With a workforce of 11,396 employees, Bruker continues to drive innovation and maintain its competitive edge in the scientific instruments market.
What Products and Services Does BRKR Offer?
- Develops and manufactures scientific instruments.
- Provides analytical and diagnostic solutions.
- Offers life science tools and systems.
- Specializes in mass spectrometry and microscopy.
- Provides solutions for pathogen identification.
- Offers X-ray and atomic force microscopy instruments.
- Develops superconducting materials and devices.
How Does BRKR Make Money?
- Sells scientific instruments and analytical solutions to research institutions, pharmaceutical companies, and industrial customers.
- Generates revenue through product sales, service contracts, and software licenses.
- Focuses on innovation and product development to maintain a competitive edge.
- Utilizes a direct sales force and distribution network to reach global markets.
What Industry Does BRKR Operate In?
Bruker Corporation operates in the medical devices industry, which is characterized by continuous technological advancements and increasing demand for sophisticated analytical solutions. The global scientific instruments market is projected to grow, driven by increasing research and development spending, particularly in the pharmaceutical and biotechnology sectors. Bruker competes with companies like BrightSpring Health Services, Inc. (BTSG), Krystal Biotech, Inc. (KRYS), Glaukos Corporation (GKOS), Chemed Corporation (CHE), and TG Therapeutics, Inc. (TGTX), each vying for market share through product innovation and strategic partnerships. Bruker's diverse portfolio and focus on high-growth segments position it favorably in this competitive landscape.
Who Are BRKR's Key Customers?
- Research institutions and universities.
- Pharmaceutical and biotechnology companies.
- Industrial and manufacturing companies.
- Clinical and diagnostic laboratories.
FY2026 estForward Outlook
Wall Street analysts project Bruker Corporation revenue of about $3.59B for fiscal 2026, with EPS near $2.12. The estimate reflects 8 contributing analysts.
ROE -1%Key Financial Metrics
Return on equity for Bruker Corporation stands at -0.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Bruker Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.70 places it in the grey zone, a middle ground that warrants monitoring.
BRKR Valuation & Market Position
With a $8.55B market cap, Bruker Corporation sits in the mid-cap segment of the market. Relative to its peer group, BRKR's quantitative score of 56/100 is below the peer average of 77/100.
BRKR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests strong confidence in the company's future performance, indicating positive expectations among leadership.
- Community sentiment has shifted positively, with discussions highlighting Bruker's innovative technologies and their potential market impact.
- Analysts are increasingly recognizing Bruker's strategic acquisitions, which are expected to enhance its competitive edge and market share.
- The growing demand for analytical instruments in various sectors aligns well with Bruker's offerings, positioning them favorably in the market.
Bear Case
- Concerns about potential supply chain disruptions have emerged, which could impact production timelines and operational efficiency.
- Some community voices express skepticism about the sustainability of Bruker's recent growth, questioning whether it can maintain momentum.
- Market sentiment has been cautious due to broader economic uncertainties, leading to a more bearish outlook among some investors.
- Recent earnings reports have raised questions about profit margins, with some analysts suggesting that rising costs could pressure future profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
BRKR Latest News
-
Earnings Scheduled For May 6, 2026
benzinga · May 6, 2026
-
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
benzinga · Nov 20, 2025
-
Earnings Scheduled For August 4, 2025
benzinga · Aug 4, 2025
BRKR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRKR.
Price Targets
Consensus target: $50.50
BRKR MoonshotScore
What does this score mean?
The MoonshotScore rates BRKR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest Bruker Corporation Analysis
Leadership: Frank H. Laukien
Chairman, President and Chief Executive Officer
Frank H. Laukien has served as the Chairman, President, and CEO of Bruker Corporation, managing a workforce of 11,396 employees. His career spans several decades in the scientific instruments and technology sectors. Laukien holds a Ph.D. in Physics from Harvard University and has extensive experience in business development, strategic planning, and operational management. His leadership has been instrumental in driving Bruker's growth and innovation.
Track Record: Under Frank H. Laukien's leadership, Bruker Corporation has expanded its product portfolio, strengthened its market position, and achieved significant milestones in technological innovation. Key achievements include strategic acquisitions, successful product launches, and increased market share in key segments. His focus on research and development has driven the company's growth and enhanced its competitive advantage.
Bruker Corporation Healthcare Stock: Key Questions Answered
What does the AI Score mean for BRKR?
BRKR holds an AI Score of 56/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Bruker Corporation develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions. The company operates through three segments: Bruker Scientific Instruments …
What does Bruker Corporation do?
Bruker Corporation develops, manufactures, and distributes scientific instruments and analytical solutions used in life science research, materials science, and industrial applications. The company's product portfolio includes mass spectrometers, magnetic resonance systems, X-ray diffractometers, atomic force microscopes, and other advanced analytical tools.
What do analysts say about BRKR stock?
Analyst consensus on Bruker Corporation (BRKR) reflects a generally positive outlook, driven by the company's strong market position, diverse product portfolio, and growth opportunities in key segments. Key valuation metrics, such as price-to-earnings ratio and enterprise value-to-EBITDA, are closely monitored to assess the company's financial performance and growth potential.
What are the main risks for BRKR?
The main risks for Bruker Corporation include intense competition from established players and new entrants in the scientific instruments market. Economic downturns and reduced research funding can negatively impact the demand for Bruker's products. Technological obsolescence and disruptive innovations pose a threat to the company's existing product lines.
How does Bruker Corporation navigate regulatory approval processes?
Bruker Corporation navigates regulatory approval processes by adhering to stringent quality control standards and compliance requirements. The company's diagnostic solutions, such as the MALDI Biotyper platform, are subject to regulatory oversight by agencies like the FDA in the United States and the EMA in Europe. Bruker maintains a dedicated regulatory affairs team that ensures compliance with applicable regulations and guidelines.
What is Bruker Corporation's drug pipeline status?
Bruker Corporation does not have a traditional drug pipeline in the same way as pharmaceutical companies. Instead, Bruker focuses on providing analytical tools and solutions that support drug discovery and development. The company's mass spectrometry, microscopy, and molecular diagnostics platforms are used by pharmaceutical companies and research institutions to identify drug targets, analyze drug candidates, and monitor drug efficacy.
What are the key factors to evaluate for BRKR?
Bruker Corporation (BRKR) holds an AI score of 56/100 (moderate). Analysts target $50.50 (-10%). Not financial advice.
How frequently does BRKR data refresh on this page?
BRKR's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BRKR's recent stock price performance?
Bruker Corporation (BRKR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across life science, NANO, and energy sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent filings and may not reflect current performance.